Showing 1871-1880 of 3038 results for "".
- Blanchard Contact Lenses Adds Paragon CRT to Product Portfoliohttps://modernod.com/news/blanchard-contact-lenses-adds-paragon-crt-to-product-portfolio/2478464/Blanchard Contact Lenses announced that it has expanded its product portfolio in the United States to include Paragon CRT and Paragon CRT Dual Axis ortho-k lenses. Paragon CRT and Paragon CRT Dual Axis are reverse geometry corneal lenses manufactured in high-Dk gas permeable lens material
- Nova Eye Medical Establishes “AlphaRET” to Fulfill the Commercial Development of 2RThttps://modernod.com/news/nova-eye-medical-establishes-alpharet-to-fulfill-the-commercial-development-of-2rt/2478458/Nova Eye Medical has announced the reorganization of its 2RT assets via the establishment of AlphaRET Pty Ltd. Establishing AlphaRET, a wholly owned subsidiary of Nova Eye Medical Limited, will enable the company to better concentrate its commercialization efforts for 2RT, and delineate th
- Pfizer CEO Says Late November is Earliest Possible Filing Date for COVID-19 Vaccine in UShttps://modernod.com/news/pfizer-ceo-says-late-november-is-earliest-possible-filing-date-for-covid-19-vaccine-in-us/2478428/Pfizer CEO Albert Bourla said that the earliest the company will apply for FDA emergency-use authorization (EUA) for its COVID-19 vaccine program would be shortly after a key safety milestone is met, which is currently expected to be in the third week of November. “As we get closer to an im
- Beovu Now Available in Canada, Receives Positive Reimbursement Recommendationhttps://modernod.com/news/beovu-now-available-in-canada-receives-positive-reimbursement-recommendation/2478363/Novartis Pharmaceuticals Canada has announced that Beovu (brolucizumab injection) is now available in Canada for the treatment of wet age-related macular degeneration (AMD). The anti-VEGF therapy for wet AMD offers the option for eligible patients to start on 3-mo
- Visus Therapeutics Launches and Announces Clinical Development Program for Novel Presbyopia Eye Drophttps://modernod.com/news/visus-therapeutics-launches-and-announces-clinical-development-program-for-novel-presbyopia-eye-drop/2478333/Visus Therapeutics announced its launch and clinical development program for a novel eye drop designed to restore the loss of near vision associated with presbyopia. Visus’ lead product candidate is Brimochol, a proprietary formulation that combines two FDA-approved pharmaceuticals: carbachol and
- Novavax Begins Phase 3 Coronavirus Vaccine Trial in UKhttps://modernod.com/news/novavax-begins-phase-3-coronavirus-vaccine-trial-in-uk/2478330/Novavax said Thursday it has initiated its first phase 3 study to evaluate the efficacy, safety and immunogenicity of its COVID-19 vaccine candidate NVX-CoV2373. The trial, which is being conducted in the UK, is expected to enroll up to 10,000 individuals between the ages of 18 and 84 years, with
- Whitney Hauser, OD, FAAO, Joins Novartis Ophthalmicshttps://modernod.com/news/whitney-hauser-od-faao-joins-novartis-ophthalmics/2478318/Novartis has announced that Whitney Hauser, OD, FAAO, will be joining the team as Director, Peer Education for US Ophthalmics. In this capacity, Dr. Hauser will bring her experience as a professor, clinician and founder of the Dry Eye Coach to help shape Novartis’ education and engagement
- BioNTech Snaps Up Novartis’ German Site to Expand Coronavirus Vaccine Outputhttps://modernod.com/news/biontech-snaps-up-novartis-german-site-to-expand-coronavirus-vaccine-output/2478296/BioNTech announced that it signed a share purchase agreement to acquire Novartis’ manufacturing facility in Marburg, Germany, a move it says will bolster its COVID-19 vaccine production capacity by up to 750 million doses per year, or over 60 million doses per month. BioNTech, whose Pfizer-
- European Medicines Agency (EMA) Approves Safety Label Update for Novartis’ Beovuhttps://modernod.com/news/european-medicines-agency-ema-approves-safety-label-update-for-novartis-beovu/2478279/Novartis announced that the Committee for Medicinal Products for Human Use (CHMP), has approved an update to the Beovu (brolucizumab) Summary of Product Characteristics (SmPC) to include additional information regarding retinal vasculitis and retinal vascular occlusion.1 Typically, the
- Scottish Medicines Consortium Accepts Iluvien for Prevention of Relapse in Recurrent Noninfectious Uveitishttps://modernod.com/news/scottish-medicines-consortium-accepts-iluvien-for-prevention-of-relapse-in-recurrent-noninfectious-uveitis/2478259/The Scottish Medicines Consortium (SMC) has accepted Iluvien (190µg fluocinolone acetonide (FAc) intravitreal implant in applicator) for use within NHS Scotland for prevention of relapse in recurrent noninfectious uveitis affecting the posterior segment of the eye (NIU-PS) in adults.1<